CryoLife eyes FDA approval for dissolving hemostat

CryoLife is aiming to get PerClot FDA approved by 2015.--Courtesy of CryoLife

CryoLife ($CRY) won the FDA's blessing to kick off a U.S. trial of its PerClot bleeding-control device, plotting a large-scale study to snag U.S. approval.

Like other hemostats, PerClot is designed to stem bleeding during surgery, but CryoLife's technology is made up of absorbable polysaccharide granules that form a barrier to stop bleeding before harmlessly degrading after a few days.

Now, with the FDA's signoff, CryoLife plans to start enrollment for a pivotal trial in the third quarter, aiming for FDA approval in 2015. The company will study PerClot's safety and efficacy on patients undergoing surgery, looking for successful hemostasis within 5 minutes while keeping an eye on adverse events.

CryoLife estimates the U.S. hemostatic market will swell to around $1.1 billion by 2014, and, if PerClot's international performance is any indication, the company is well positioned to snag a share of that growth. The sealant won a CE mark back in 2010, and its international sales jumped 34% last quarter compared to the previous year, the company said.

The Atlanta-headquartered company has been expanding its reach across surgical devices and tissue treatments, last year paying $17 million for Hemosphere and its graft to treat end-stage renal disease. In 2011, CryoLife bought Cardiogenesis for $22 million, absorbing that company's surgical technologies for coronary artery disease.

- read CryoLife's statement

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.